This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at understanding the drivers of metastasis in small cell lung cancer (SCLC). The project leverages the university's recently developed method to generate functionally viable pulmonary neuroendocrine cells (PNECs) from human pluripotent stem cells, which can be transformed to replicate key stages of SCLC from...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $642,429 to The University of Texas Southwestern Medical Center to conduct research on acquired cross-resistance in small cell lung cancer (SCLC). The research aims to understand how molecular alterations, particularly extrachromosomal MYC amplifications, drive chemotherapy resistance in SCLC tumors. Key aspects include developing patient-derived xenograft models to study...
This Project Grant award of $1,592,358 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will fund research at The Leland Stanford Junior University (Stanford University) to determine how cystine/cysteine (CYS) metabolism regulates cell state-specific vulnerabilities and lethal mechanisms in small cell lung cancer (SCLC). The key objectives are to: 1) Understand how distinct neuroendocrine SCLC cell states dictate the choice to die by apoptosis versus ferroptosis; 2)...
This $424,836 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to characterize and target drug-tolerant persister cells (DTPCs) in small cell lung cancer (SCLC). The project will: 1) Collect and molecularly profile DTPCs from SCLC models and patient samples to track their emergence and trajectory; 2) Assess the ability of a novel SCLC therapy (a bispecific T-cell engager targeting DLL3) to eliminate the post-platinum DTPC population; and 3)...
This Project Grant award, titled "METABOLIC CONTROL OF MALIGNANT FATES IN LUNG CANCER", is funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $730,400 award, with a period of performance from December 1, 2024 to November 30, 2029, will support research conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New York, NY. The research aims to determine how specific...
The National Cancer Institute (NCI) awarded a $3,787,956 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, titled "Investigating and Targeting Replication Stress in Small Cell Lung Cancer," aims to advance the understanding of molecular mechanisms underlying DNA replication stress and identify novel therapeutic strategies to combat acquired chemoresistance in small cell lung cancer (SCLC). The research...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research into a novel tumor suppression pathway in small cell lung cancer (SCLC). The research aims to leverage genetically engineered mouse models and cellular systems to elucidate the biological roles of the SAPK/AP-1 pathway in SCLC tumor initiation and progression....
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675 to The University of Texas Southwestern Medical Center to investigate the potential of Jumonji lysine demethylases as therapeutic targets for small cell lung cancer (SCLC). The key objectives are to: Evaluate the efficacy of Jumonji inhibitors as first-line therapy for SCLC, including in models resistant to current standard-of-care etoposide chemotherapy. Assess the combination...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $216,972 to Temple University to conduct research focused on understanding and targeting the unique vulnerabilities that drive replication stress and G1/S transition issues in small cell lung cancer (SCLC). The research aims to elucidate the mechanistic role of low levels of the LMNA nuclear structural protein in causing increased replication stress in SCLC, as well as determine...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $122,834 to Duke University to investigate how inhibiting the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) cells to metabolic dysregulation, leading to cell death. The research aims to determine how ABL kinases mediate metabolic function, the mechanism of metabolic dysregulation following ABL inhibition, and the extent to which combining ABL kinase inhibition with inhibition of MCT transporters induces ferroptotic cell death in SCLC. Approaches will include metabolic profiling, Seahorse assays, in vitro drug treatments, and in vivo mouse model experiments. This work explores a novel mechanism of ABL kinase regulation of mitochondrial homeostasis and evaluates a potential treatment modality for SCLC patients.